Drug development company Poolbeg Pharma (AIM: POLB) (OTCQB: POLBF) announced on Tuesday that it has entered into a strategic collaboration with a Nasdaq-listed biopharma company to develop an optimized oral drug for a metabolic condition using Poolbeg's licensed oral delivery technology.
The agreement includes funding for producing a prototype drug, aiming to enhance the delivery of the partner's novel drug to its therapeutic site. Poolbeg is optimistic about the collaboration evolving into a full licensing agreement, integrating the oral delivery technology into the biopharma's pipeline. This collaboration signifies a crucial step for Poolbeg towards early revenues and reinforces its commitment to advancing treatments for metabolic conditions.
Poolbeg Pharma specialises in innovative medicines for infectious and prevalent diseases, employing a disciplined portfolio approach to accelerate drug development. The company targets the growing infectious disease market, which is projected to exceed USD250bn by 2025.
With access to assets from hVIVO plc, Poolbeg leverages over 20 years of human challenge trial data, progressing programs in oncology and metabolic syndromes. Notable assets include POLB 001, a small molecule immunomodulator for severe influenza, POLB 002, an intranasally administered RNA-based immunotherapy and POLB 003, a vaccine candidate for Melioidosis. Poolbeg Pharma utilizes AI for target identification, asset acquisition and pipeline expansion, showcasing a diverse and promising portfolio.
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI
Technavio predicts increase in global peptide therapeutics market size
GSK secures global rights to CureVac's mRNA vaccines in new licensing deal
Biophytis reports positive Phase 2/3 results for COVID-19 treatment at WCID
SCG Cell Therapy's SCG142 IND application receives US FDA approval
EDX Medical to distribute cResponse cancer assay in UK and Nordics
Scancell Holdings announces evaluation agreement with major biotechnology company
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
YS Biopharma repays USD40m loan facility
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib